Treatment of acquired autoimmune myasthenia gravis: a topic review.
We propose a new approach to staging the disease based on clinical and immunological response to treatment. We oppose clinical remission to immunological remission and define total clinical remission as the goal of therapy. We describe the use, side effects and indications of established therapies. Acetylcholine esterase inhibitors are only a symptomatic treatment as is plasma exchange. Usefulness and limits of thymectomy, corticosteroids and immunosuppressants are described here. Their goal is to reduce the auto-immune process. Long-term hazards from these medications are described and methods to reduce their potential risks are suggested. We suggest the number of patients having life threatening complications while undergoing aggressive immunosuppression can be reduced by a systematic approach to follow-up. In the second part of this review article, adapting management to specific situations is emphasized in refractory disease, respiratory failure, neonatal and juvenile forms of the disease. The special situation of seronegative myasthenia is discussed.
Verma
P
P
Department of Medicine/Neurology, University Hospital, Vancouver, British Columbia, Canada.
Oger
J
J
D001327:Autoimmune Diseases / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*